Quantcast
Last updated on April 16, 2014 at 8:44 EDT

Latest Pemetrexed Stories

2013-08-01 08:32:15

The ORCA(TM) Program Continues to Expand with Patient Enrollment Now Open for First Phase 2 Trial of OGX-427 in Non-Small Cell Lung Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 1, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Spruce(TM) clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 trial evaluating OGX-427, a heat shock protein 27 (Hsp27) inhibitor, in patients...

2013-06-13 08:25:59

Changes in Reimbursement Policy and an Increasing Incident Population Will Drive Growth Despite Price Cuts in Market, According to a New Report from Decision Resources BURLINGTON, Mass., June 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual rate of 7 percent, reaching $73...

2013-06-04 08:30:42

Results Presented at ASCO 2013 Establish the Safety Profile of MM-121 and Show Preliminary Activity of the Combination of MM-121 and Gemcitabine or Carboplatin or Pemetrexed or Cabazitaxel CAMBRIDGE, Mass., June 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be combined with standard doses of certain cytotoxic agents for investigation as treatment...

2013-06-03 08:27:58

CHICAGO, June 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced results from its PRONOUNCE trial of ALIMTA® (pemetrexed for injection) for treatment of nonsquamous non-small cell lung cancer (NSCLC) that was presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The PRONOUNCE trial compared an ALIMTA (pemetrexed), carboplatin doublet regimen to a paclitaxel, carboplatin and bevacizumab triplet regimen. The study did not...

2013-05-23 08:26:41

OGX-427 ORCA(TM) Program Expands to Include Second Phase 2 Trial in Patients with Advanced Lung Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, May 23, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar(TM) clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial will be the...

2013-05-15 20:23:01

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

2013-04-11 08:28:48

Company Expands Development Program with Fifth Phase 2 Clinical Trial in the OGX-427 ORCA(TM) Program BOTHELL, Wash. and VANCOUVER, British Columbia, April 11, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 study evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small cell lung...

2012-12-14 05:03:13

Mesothelioma Law Firm Remains Dedicated to Informing Mesothelioma Patients and Caregivers About the Latest Advancements in Mesothelioma Treatment and Research DALLAS (PRWEB) December 13, 2012 The national mesothelioma law firm of Baron and Budd is pleased to report that Aduro Bio has begun conducting phase II clinical trials on a new cancer vaccine known as CRS-207. The company has already enlisted the first group of mesothelioma patients who will take the experimental vaccine. CRS-207...

2012-10-17 15:23:43

INDIANAPOLIS, Oct. 17, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients may receive ALIMTA(®) (pemetrexed for injection) as a maintenance therapy following first-line ALIMTA plus cisplatin for locally advanced or metastatic nonsquamous non-small cell lung cancer (NS NSCLC). The FDA approved the label inclusion of Phase III data that demonstrated progression-free and overall survival advantages in the continuation maintenance setting for these patients....

2012-09-29 02:20:06

INDIANAPOLIS, Sept. 29, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Results were presented today during the Lung Cancer - Metastatic Poster Session at the ESMO 2012 Congress (European Society for Medical Oncology), 1:00 p.m. - 2:00 p.m. CET, in Vienna, Austria. Interim data for a study in chemotherapy-naive patients with advanced NSCLC treated with...